152 related articles for article (PubMed ID: 36070368)
1. Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy.
Gu Z; Yao Y; Yang G; Zhu G; Tian Z; Wang R; Wu Q; Wang Y; Wu Y; Chen L; Wang C; Gao J; Kang X; Zhang J; Wang L; Duan S; Zhao Z; Zhang Z; Sun S
Sci Transl Med; 2022 Sep; 14(661):eabo5987. PubMed ID: 36070368
[TBL] [Abstract][Full Text] [Related]
2. Uncovering drug repurposing candidates for head and neck cancers: insights from systematic pharmacogenomics data analysis.
Chai AWY; Tan AC; Cheong SC
Sci Rep; 2021 Dec; 11(1):23933. PubMed ID: 34907286
[TBL] [Abstract][Full Text] [Related]
3. Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
Nichols AC; Black M; Yoo J; Pinto N; Fernandes A; Haibe-Kains B; Boutros PC; Barrett JW
BMC Pharmacol Toxicol; 2014 Nov; 15():66. PubMed ID: 25428177
[TBL] [Abstract][Full Text] [Related]
4. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
[TBL] [Abstract][Full Text] [Related]
5. Genomic sequencing and precision medicine in head and neck cancers.
Hoesli RC; Ludwig ML; Michmerhuizen NL; Rosko AJ; Spector ME; Brenner JC; Birkeland AC
Eur J Surg Oncol; 2017 May; 43(5):884-892. PubMed ID: 28034498
[TBL] [Abstract][Full Text] [Related]
6. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
[TBL] [Abstract][Full Text] [Related]
7. Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments.
Jayawickrama SM; Ranaweera PM; Pradeep RGGR; Jayasinghe YA; Senevirathna K; Hilmi AJ; Rajapakse RMG; Kanmodi KK; Jayasinghe RD
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2045. PubMed ID: 38522008
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetics of head and neck squamous cell carcinoma.
Saada-Bouzid E; Peyrade F; Guigay J
Curr Opin Oncol; 2019 May; 31(3):131-137. PubMed ID: 30893149
[TBL] [Abstract][Full Text] [Related]
9. Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer.
Solis RN; Silverman DA; Birkeland AC
Curr Treat Options Oncol; 2022 Feb; 23(2):254-267. PubMed ID: 35195839
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic analysis reveals key lncRNAs associated with ribosomal biogenesis and epidermis differentiation in head and neck squamous cell carcinoma.
Guo YZ; Sun HH; Wang XT; Wang MT
J Zhejiang Univ Sci B; 2018 Sept.; 19(9):674-688. PubMed ID: 30178634
[TBL] [Abstract][Full Text] [Related]
11. [FGFR-targeted therapy in head and neck carcinomas].
Dietrich D
HNO; 2021 Mar; 69(3):172-184. PubMed ID: 32519203
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
13. Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.
Hanemaaijer SH; van Gijn SE; Oosting SF; Plaat BEC; Moek KL; Schuuring EM; van der Laan BFAM; Roodenburg JLN; van Vugt MATM; van der Vegt B; Fehrmann RSN
Oral Oncol; 2018 May; 80():33-39. PubMed ID: 29706186
[TBL] [Abstract][Full Text] [Related]
14. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
[TBL] [Abstract][Full Text] [Related]
15. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
[TBL] [Abstract][Full Text] [Related]
16. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
17. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
Routila J; Qiao X; Weltner J; Rantala JK; Carpén T; Hagström J; Mäkitie A; Leivo I; Ruuskanen M; Söderlund J; Rintala M; Hietanen S; Irjala H; Minn H; Westermarck J; Ventelä S
Oral Oncol; 2022 Apr; 127():105772. PubMed ID: 35245886
[TBL] [Abstract][Full Text] [Related]
19. Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.
Xu C; Nikolova O; Basom RS; Mitchell RM; Shaw R; Moser RD; Park H; Gurley KE; Kao MC; Green CL; Schaub FX; Diaz RL; Swan HA; Jang IS; Guinney J; Gadi VK; Margolin AA; Grandori C; Kemp CJ; Méndez E
Clin Cancer Res; 2018 Jun; 24(12):2828-2843. PubMed ID: 29599409
[No Abstract] [Full Text] [Related]
20. The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma?
Farshbaf A; Lotfi M; Zare R; Mohtasham N
Pharmacogenomics J; 2023 May; 23(2-3):37-44. PubMed ID: 36347937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
